Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Evaluating Neuroprotective Effects of Caplacizumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Fahad Hannan, Susan Huang, Ting-Yim Lee, Daniel Mendes, Jonathan Thiessen, Christopher Patriquin, Katerina Pavenski

Blood (2024) 144 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2024-210952

Published: 2024

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Johanna A. Kremer Hovinga Strebel, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, PAUL Coppo, Umer Khan, Laurel A. Menapace, Ana Paula Marques, Sriya Gunawardena, Marie Scully

Blood (2022) 140 (Supplement 1): 5651–5653.

https://doi.org/10.1182/blood-2022-156306

Published: 2022

Journal Articles

Pregnancy in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Single Centre Experience and Review of Literature

Brandon Tse, Alexandra Grudzinski, Michelle Kasimov, Michelle Sholzberg, Andrea Lausman, Katerina Pavenski

Blood (2022) 140 (Supplement 1): 8501–8502.

https://doi.org/10.1182/blood-2022-169063

Published: 2022

Journal Articles

Receiver Operating Characteristics of NT-Probnp in the Transfusion Associated Dyspnea: Prospective Observation & Laboratory Assessment (TADPOL) Study of Cardiorespiratory Versus Febrile Presentation Archetypes

Blood (2022) 140 (Supplement 1): 2829–2830.

https://doi.org/10.1182/blood-2022-169195

Published: 2022

Journal Articles

Sex Differences in Anemia and Red Blood Cell Transfusions Among General Internal Medicine Inpatients

Anath C. Lionel, Riley Waters, Michelle Sholzberg, Katerina Pavenski, Amol Verma, Fahad Razak

Blood (2021) 138 (Supplement 1): 1074.

https://doi.org/10.1182/blood-2021-154106

Published: 2021

Journal Articles

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Marie Scully, Javier de la Rubia, Katerina Pavenski, Ara Metjian, Paul Knoebl, Flora Peyvandi, Spero Cataland, Paul Coppo, Johanna A. Kremer Hovinga Strebel, Jessica Minkue Mi Edou, Rui de Passos Sousa, Filip Callewaert, Sriya Gunawardena, Julie Lin

Blood (2021) 138 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2021-148839

Published: 2021

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Urgent Transfusion in a New Patient with Rare Blood Type

Catherine Dubé, MD, Scherzinger Kritikopoulos, MLT, Marsha Downie, MLT, Elizabeth Krok, MSc, BSc, ART, MLT, Katerina Pavenski, MD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-141478

Published: 2020

Journal Articles

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Brandon Tse, Gloria Lim, MDFRCPC,MSc, Michelle Sholzberg, MDBSc,FRCPC,MSc, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 2381.

https://doi.org/10.1182/blood-2019-123081

Published: 2019

Journal Articles

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

Spero Cataland, MD, Marie Scully, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Filip Callewaert

Blood (2019) 134 (Supplement_1): 4908.

https://doi.org/10.1182/blood-2019-123124

Published: 2019

Journal Articles

A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus

Jeannie Callum, Calvin Yeh, MD PhD, Mark McVey, MD, Andrew Petrosoniak, MD, Stephanie Cope, Troy Thompson, BAHSc, Victoria Chin, Keyvan Karkouti, MD, Avery Nathans, MDMPH PhD, Kimmo Murto, MD, Suzanne Beno, MD, Jacob Pendergrast, MDFRCPC, Andrew McDonald, MDMSc, Neil Adhikari, MDM MSc, Asim Alam, MD, Donald M. Arnold, MD, Lee Barratt, Andrew Beckett, MD, Sue Brenneman, MD, Hina Chaudhry, BSc, Allison Collins, MD, Margaret Harvey, Jacinthe Lampron, MD, Russell MacDonald, MDMPH, Clarita Margarido, MD, Amanda McFarlan, Barto Nascimento, MDMSc, Wendy Owens, Menaka Pai, MSc, MD FRCPC, Sandro Rizoli, MD PhD, Theodora Ruijs, MD, Robert Skeate, PhD, Teresa Skelton, MD, Michelle Sholzberg, MDBSc,FRCPC,MSc, Kelly Syer, Jami-Lynn Viveiros, Josee Theriault, MD, Alan T. Tinmouth, MD FRCPC, Rardi Van Heest, MD, Susan White, Michelle P. Zeller, MD FRCPC, MHPE, Katerina Pavenski, MD

Blood (2019) 134 (Supplement_1): 5792.

https://doi.org/10.1182/blood-2019-121501

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Carolyne Elbaz, MD, Katerina Pavenski, MD, Hina Chaudhry, BSc, Jerome M. Teitel, MD FRCPC, Michelle Sholzberg, MDBSc,FRCPC,MSc

Blood (2019) 134 (Supplement_1): 1128.

https://doi.org/10.1182/blood-2019-122260

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Johanna A. Kremer Hovinga, MD Prof, Marie Scully, MD MRCP, FRCPath, Spero R Cataland, MD, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD, Ara Metjian, MD

Blood (2018) 132 (Supplement 1): 3744.

https://doi.org/10.1182/blood-2018-99-112177

Published: 2018

Journal Articles

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Flora Peyvandi, MD PhD, Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 373.

https://doi.org/10.1182/blood-2018-99-112125

Published: 2018

Journal Articles

Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing

Hina Chaudhry, BSc, Michelle Sholzberg, MDM, MSc, FRCPC, Katerina Pavenski, MD

Blood (2018) 132 (Supplement 1): 5051.

https://doi.org/10.1182/blood-2018-99-119399

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

NARROW

Evaluating Neuroprotective Effects of Caplacizumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

The Role of ADAMTS13 Activity Levels on Disease Exacerbation or Relapse in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura: Post Hoc Analysis of the Phase 3 HERCULES and Post-HERCULES Studies

Pregnancy in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP): Single Centre Experience and Review of Literature

Receiver Operating Characteristics of NT-Probnp in the Transfusion Associated Dyspnea: Prospective Observation & Laboratory Assessment (TADPOL) Study of Cardiorespiratory Versus Febrile Presentation Archetypes

Sex Differences in Anemia and Red Blood Cell Transfusions Among General Internal Medicine Inpatients

Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study

Redefining outcomes in immune TTP: an international working group consensus report

Urgent Transfusion in a New Patient with Rare Blood Type

Describing the Point Prevalence and Characteristics of Venous Thromboembolism in Patients with Thrombotic Thrombocytopenic Purpura

Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

A Regional Massive Hemorrhage Protocol: Designed with a Modified Delphi Technique to Obtain Consensus

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study

Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura

Adamts-13 Inhibitor Testing Is Often Negative on Initial Testing

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only